For the treatment of prophylaxis of deep vein thrombosis.
The antithrombotic activity of Fondaparinux is the result of antithrombin III (ATIII)-mediated selective inhibition of Factor Xa. By selectively binding to ATIII, Fondaparinux potentiates (about 300 times) the innate neutralization of Factor Xa by ATIII. Neutralization of Factor Xa interrupts the blood coagulation cascade and thus inhibits thrombin formation and thrombus development.
100%
17-21 hours
In individuals with normal kidney function, fondaparinux is eliminated in urine mainly as unchanged drug.
* 7 to 11 L [healthy adults]